type II diabetes

[Fractyl Health, Inc.] Fractyl Health announced that the company has received approval from the FDA for an Investigational Device Exemption (IDE) to begin its Revitalize-2 pivotal study.

[Life Sciences] Scientists provide a comprehensive overview of how hyperglycemia in type 2 diabetes reprograms endothelial epigenome and lead to functional consequences in the pathogenesis of vascular complications.

[JCI Insight] Scientists found that Notch activation in postnatal β cells impaired glucose-stimulated insulin secretion and glucose intolerance, but also observed a remnant glucose intolerance after doxycycline withdrawal and cessation of Notch activity, associated with a marked disruption of normal islet architecture.

[Journal of Genetics and Genomics] The authors summarize the roles and underlying mechanisms of transcription factors in the maintenance of β-cell identity under physiological and type 2 diabetic conditions.

[Inventiva] Inventiva announced that the US FDA has completed its safety review of the IND application and concluded that the proof-of-concept Phase II combination trial, with its lead drug candidate lanifibranor and the SGLT2 inhibitor empagliflozin1 in patients with Type 2 Diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH), may proceed.

[Proceedings of the National Academy of Sciences of the United States of America] Using global stimulator of interferon genes (STING) knockout (STING−/−) and β-cell–specific STING knockout (STING-βKO) mouse models, scientists revealed a distinct role of STING in the regulation of glucose homeostasis through peripheral tissues and β-cells.